spacer
home > pmps > autumn 2008 > coated for success
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Coated for Success

As anyone in the pharma industry knows, smart money no longer bets on big returns from blockbuster drugs. As a recent PricewaterhouseCoopers report noted, new molecules are scarcer than they have been for many years. In 2007, for example, the FDA approved only 19 new molecular entities and biologics – fewer than in any year since 1983 (1).

Meanwhile, the patents protecting blockbuster molecules developed during the 1980s and 1990s are already expiring, permitting generic manufacturers to cash in on the innovators’ costly research. US research firm Sanford C. Bernstein has estimated that, due to generic market share erosion, the top 10 pharma companies will lose between two and 40 per cent of their revenue between 2008 and 2012 (1).

At the same time, the cost of developing new molecules has soared. At the 2006 Drug Discovery Conference held in Boston, it was estimated that the cost of producing a successful new drug could now exceed $2 billion (2).

ADAPT AND SURVIVE

In the face of this turmoil, pharma companies are radically adapting their businesses simply in order to survive. Two very different markets are emerging...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hans Huttinga is the Strategic Marketing Director (Pharma Ingredients) of Kerry Bioscience – Sheffield Pharma Ingredients. Hans, who has worked for the Kerry Bioscience organisation since 2000, has accrued more than 16 years of experience in new business, commercialisation and development of highly valued pharmaceutical ingredients and life science products within the life science and pharma markets. He graduated as an Engineer in Biotechnology in 1989, and has a long track record in business creation, sales and marketing within profitable companies serving the excipient and cell nutrition markets, and supplying the pharmaceutical and biotechnology industries.
spacer
Hans Huttinga
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement